MedTrace Logo

Combination Chemotherapy for the Treatment of Indian Kala-Azar

NCT00370825 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2008-09-12

No results posted yet for this study

Summary

The investigators are using a sequential design to combine miltefosine and AmBisome in different doses.

Conditions

  • Visceral Leishmaniasis

Interventions

DRUG

Combination therapy with AmBisome and miltefosine

Sponsors & Collaborators

  • Banaras Hindu University

    lead OTHER

Principal Investigators

  • Shyam Sundar, MD · Banaras Hindu University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370825 on ClinicalTrials.gov